Kerecis°

Kerecis® Omega3 MariGen™

Intact fish-skin grafts for tissue regeneration



About MariGen™

Kerecis Omega3 MariGen is intact fish skin used to support tissue regeneration and healing chronic wounds. MariGen products have successfully treated countless number of patients around the world. The fish-skin grafts have prevented many amputations, helping improve the patients' quality of life⁷ and potentially increasing their life spans.

Kerecis® Omega3 Technology

Kerecis Omega3 MariGen is intact fish skin that is homologous to human¹ skin, used for tissue regeneration and grafting.² Kerecis[®] Omega3 MariGen is FDA approved and CE marked for multiple clinical applications.

Because there is no risk of a viral disease transfer from Atlantic cod to humans, the fish skin needs only mild processing for medical use and maintains its natural structure and elements, including Omega3 fatty acids.^{3,4} When grafted onto damaged human tissue, such as a burn or a wound, the fish skin recruits the body's own cells, supporting its ability to regenerate.²

The superior clinical and economic performance of Kerecis Omega3 MariGen has been demonstrated in three blinded, randomized, controlled clinical trials^{2,5,6} and in numerous other clinical studies.^{7,8,12-16}

Kerecis Omega3 MariGen is Homologous to Human Skin



Scanned electron microscopy images of human skin (left) and Kerecis® Omega3 MariGen (right) show the structural similarities between the skin types.

Product Features

- Easy to Apply⁹
- Homologous to Human Skin¹
- Improved Wound Closure Rates^{4,5,6}
- Better Functional Outcome¹⁷
- No Chemical Cross-linking¹

- Dermal and Epidermal Layers Intact¹
- Natural Microbial Barrier and Wound Cover^{2,3,4}
- Strong, Robust and Conforms to the Wound Bed¹
- Three-dimensional Structure and Natural Porosity Preserved¹

Early Cellular Ingrowth

The Kerecis® Omega3 MariGen intact fish skin graft facilitates significantly more three dimensional cellular ingrowth than in amnion/chorion tissue. The fish skin is thicker, and more porous, than mammalian matrixes and human amnion/ chorion membranes.

The unique biomechanical properties of the fish skin and the size of its pores facilitate cell ingrowth, a critical step for tissue regeneration. In-vitro tests of the fish skin shows significantly more (p<0.0001) three-dimensional cell ingrowth than human amnion/chorion membranes.



Top row: Scanned electron microscopy images of fish skin show a pore size of ~10-150 µm. This is suitable for human cell infiltration because typical human cells range from ~10-100 μ m in diameter.

Amnion/chorion membrane has an average pore size of 1.3 µm which is more than 10 times smaller than typical human cells.

Lower row: Confocal microscopy images following cell seeding and fluorescent labeling, indicated with red arrows, show examples of cell infiltration in fish skin and human amnion/chorion.

Scale bar on all images 100µm.

Proven Results

% Percentage of Wounds Healed

Kerecis Omega3 MariGen exhibits superior in two separate randomized controlled trials published in peer-review journal.



Ordering Information Kerecis[®] Omega3 MariGen™

Catalog # Box of 10	Catalog # Single Units	Description	Billable Units
50200S16B2D	50200S16B0D	Kerecis Omega3 MariGen, 16 mm, circular	2
50200S00B2D	50200S00B0D	Kerecis Omega3 MariGen, 1.75 x 1.75 cm	4
50200S01B2D	50200S01B0D	Kerecis Omega3 MariGen, 3 x 3.5 cm	11
50200S02B2D	50200S02B0D	Kerecis Omega3 MariGen, 3 x 7 cm	21
50200S05B2D	50200S05B0D	Kerecis Omega3 MariGen, 5 x 7 cm	35
50200S04B2D	50200S04B0D	Kerecis Omega3 MariGen, 7 x 7 cm	49
50200S03B2D	50200S03B0D	Kerecis Omega3 MariGen, 7 x 10 cm	70
50200F01B2D	50200F01B0D	Kerecis Omega3 MariGen, 3 x 3.5 cm, fenestrated	11
50200F02B2D	50200F02B0D	Kerecis Omega3 MariGen, 3 x 7 cm, fenestrated	21
50200F03B2D	50200F03B0D	Kerecis Omega3 MariGen, 7 x 10 cm, fenestrated	70
50200P00B2D	50200P00B0D	Kerecis Omega3 MariGen Micro, 4 cm ²	4
50200P01B2D	50200P01B0D	Kerecis Omega3 MariGen Micro, 8 cm ²	8
50200P02D2D	50200P02D0D	Kerecis Omega3 MariGen Micro, 19 cm ²	19
50200P04D2D	50200P04D0D	Kerecis Omega3 MariGen Micro, 38 cm ²	38

Indications for Use

- Diabetic ulcers
- Chronic vascular ulcers
- Venous ulcers
- Pressure ulcers
- Draining wounds
- Partial and fullthickness wounds
- Trauma wounds: abrasions, lacerations, second-degree burns, skin tears
- Surgical wounds: donor sites/grafts, post-Mohs surgery, post-laser surgery, podiatric, wound dehiscence

References

1) Magnusson, S., Baldursson, B. T., Kjartansson, H., Rolfsson, O. & Sigurjonsson, G. F. Regenerative and Antibacterial Properties of Acellular Fish Skin Grafts and Human Amnion/Chorion Membrane: Implications for Tissue Preservation in Combat Casualty Care. Mil. Med. 182, 383–388 (2017). 2) Magnusson, S. et al. Decellularized fish skin: characteristics that support tissue repair. Laeknabladid 101, 567–573 (2015). 3) Rakers, S. et al. 'Fish matters': the relevance of fish skin biology to investigative dermatology. Exp. Dermatol. 19, 313–324 (2010). 4) Baldursson, B. T. et al. Healing rate and autoimmune safety of full-thickness wounds treated with fish skin acellular dermal matrix versus porcine small-intestine submucosa: a noninferiority study. Int. J. Low. Extrem. Wounds 14, (2015). 5) Kirsner, R. S. et al. Double-Blind, Prospective, Randomized Clinical Trial on 170 Acute Wounds Shows Significantly Faster Healing Rate with Intact Fish Skin Compared to Human Amniotic Membrane. Natl. Am. Podiatr. Med. Assoc. Annu. Sci. Meet. (2018). 6) Lullove E. J. et al. A multicenter, blinded, randomized controlled clinical trial evaluating the effect of Omega-3-rich fish skin in the treatment of chronic, nonresponsive diabetic foot ulcers. Wounds. Published online April 15, 2021. 7) Winters C, Kirsner RS, Margolis DJ, Lantis JC. Cost Effectiveness of Fish Skin Grafts Versus Standard of Care on Wound Healing of Chronic Diabetic Foot Ulcers: A Retrospective Comparative Cohort Study. Wounds. 2020;32(10):283-290. 8) Stone R 2nd, Saathoff EC, Larson DA, et al. Accelerated Wound Closure of Deep Partial Thickness Burns with Acellular Fish Skin Graft. Int J Mol Sci. 2021;22(4):1590. 9) Pujji 0, Jeffery SLA, Safe burn excision prior to military repatriation: an achievable goal? BMJ Military Health 2018;164:358-359. 10) Chun K. Yang, John C. Lantis II & Thais O. Polanco. A prospective, single-center, non-blinded, noncomparative, post-market compassionate cli-nical evaluation of a Novel Acellular Fish Skin Graft which contains Omega3 fatty acids, for the closure of hard to heal lower extremity chronic ulcers. Wounds 28, 112–118 (2016). 11) T. T. Trinh, F. Dünschede, C.-F. Vahl & B. Dorweiler. Marine Omega3 Wound Matrix for the Treatment of Complicated Wounds. Phlebologie 45, 93–98 (2016). 12) Dorweiler, B. et al. Die marine Omega-3-Wundmatrix zur Behandlung komplizierter Wunden. Gefässchirurgie 22, 558–567 (2017). 13) Woodrow, T., Chant, T. & Chant, H. Treatment of diabetic foot wounds with acellular fish skin graft rich in omega-3: a prospective evaluation. J. Wound Care 28, 76–80 (2019). 14) Sitje, T. S., Grøndahl, E. C. & Sørensen, J. A. Clinical innovation: fish-derived wound product for cutaneous wounds. Wounds Int. 2018 9, 44–50 (2018). 15) Patel, M. & Lantis II, J. C. Fish skin acellular dermal matrix: potential in the treatment of chronic wounds. Chronic Wound Care Manag. Res. 6, 59–70 (2019). 16) Sibbald R., Goodman L., Woo K. et al (2011) Special considerations in wound bed preparation 2011: An update. Adv Skin Wound Care. 24(9):415-36. 17) Wallner C. et al. A Comparison of Intact Piscine Skin, Split-thickness Skin Graft, and Lactic Acid Membrane in Treating Superficial and Deep Burn Wounds Following Enzymatic Debridement, J Burn Care Res, 2021; 42 (Suppl 1): 125-126 18) Alam K, Jeffery SLA. Acellular Fish Skin Grafts for Management of Split Thickness Donor Sites and Partial Thickness Burns: A Case Series. Mil Med. 2019;184(Suppl 1):16-20. doi:10.1093/ milmed/usy280



OUR VISION

To become the world leade in tissue regeneration by sustainably harnessing nature's own remedies

KERECIS REIMBURSEMENT HOTLINE

Phone: (844) KERECIS | (844) 537-3247 FAX: (844) 529-3247 HCPCS Code: Q4158 Email: reimbursement@kerecis.com

FDA approved, U.S. and international patents and trademarks granted and pending.

KERECIS

2300 Clarendon Boulevard Suite 1210 Arlington, Virginia 22201 Phone: (703) 287-8752 Email: info@kerecis.com

www.kerecis.com